(Q50663391)

English

Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study

scientific article published on 29 February 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Alzheimer's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ruth Remington

1

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Cynthia Bechtel

2

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

David Larsen

3

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Annemarie Samar

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Robert Page

5

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Christopher Morrell

6

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Thomas B Shea

7

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

publication date

29 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Journal of Alzheimer's Disease

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

51

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

991-995

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Preventing Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A potential design flaw of randomized trials of vitamin supplements

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

CLOX: an executive clock drawing task

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Clinical validity of the Mattis Dementia Rating Scale in detecting dementia of the Alzheimer type: a double cross-validation and application to a community-dwelling sample

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Towards an aging-specific cognitive phenotype: the freedom house study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Disease progression meta-analysis model in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Mediterranean Diet and Risk of Dementia

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionine

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Identifiers

10.3233/JAD-151098

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50663391&oldid=2256202553"